Hikma signs exclusive licensing, distribution and supply agreement with Basilea Pharmaceutica International Ltd. for Zevtera®

London, 15 October 2015 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that its wholly owned subsidiary Hikma Pharmaceuticals LLC (“Hikma”) has entered into an exclusive licensing, supply and distribution agreement with biopharmaceutical company

Press Release Corporate 15 October 2015

Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Zevtera® in all its MENA markets leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise. Zevtera® has received approvals in 13 European countries and Canada for the treatment of adult patients with community- and hospital-acquired pneumonia (CAP, HAP), excluding ventilator-associated pneumonia (VAP), and has been launched in Germany, France, Italy and the UK.

Mazen Darwazah, Vice-Chairman and CEO of MENA and Emerging Markets said, “Our partnership with Basilea will allow us to bring more innovative anti-infective products to the MENA, enhancing our growing portfolio of differentiated high value products and reinforcing our commitment to increasing patients’ access to high-quality medicines.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.